Finding ACCORD in the Management of Type 2 Diabetes?

Elliott, William T.
May 2010
Travel Medicine Advisor;May2010 Supplement, p1
The article explores the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study in the U.S. It examines three factors of care in type 2 diabetes that ACCORD focused, centering on the impact of intensive glucose lowering, intensive blood pressure control and combination of lipid therapy. It also accounts the action of the U.S. Food and Drug Administration (FDA) on the use of type 2 diabetes medications clopidogrel, dexlansoprazole and tamsulosin.


Related Articles

  • Finding ACCORD in the Management of Type 2 Diabetes?  // OB/GYN Clinical Alert;May2010 Pharmacology, p1 

    The article discusses the significance of the findings of the Action to Control Cardiovascular Risk in Diabetics (ACCORD) trial for management of type 2 diabetes. It notes that ACCORD examines three aspects of care in type 2 diabetes including the effects of intensive glucose lowering and the...

  • Depression.  // Current Medical Literature: Diabetes;2012, Vol. 29 Issue 3, p97 

    The article discusses research on depression and type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial program is composed of glycemic, blood pressure (BP), and lipid-lowering therapy. Depression was found to predict all-cause mortality but not the primary...

  • Finding ACCORD in the Management of Type 2 Diabetes? Elliott, William T. // Clinical Oncology Alert;May2010 Supplement, p1 

    The article examines the Action to Control Cardiovascular Risk in Diabetics (ACCORD) trial conducted to assess the efficacy of clopidogrel, dexlansoprazole and tamsulosin in treating type 2 diabetes. The trial, published in the March issue of "New England Journal of Medicine," tested the effects...

  • Olmesartan and Hydrochlorothiazide.  // AHFS Consumer Medication Information;Oct2017, p1 

    Combination product

  • Predictors of Impaired Glucose Regulation in Patients with Non-Alcoholic Fatty Liver Disease. Hatziagelaki, Erifili; Karageorgopoulos, Drosos E.; Chounta, Athina; Tsiavou, Anastasia; Falagas, Matthew E.; Dimitriadis, George // Experimental Diabetes Research;2012, Special section p1 

    Introduction. Many patients with non-alcoholic fatty liver disease (NAFLD) have impaired glucose regulation or type 2 diabetes mellitus (DM). We investigated characteristics of NAFLD patients associated with hyperglycemia. Methods. During a 2-hour oral glucose tolerance test (OGTT), serum...

  • A new drug belonging to a novel class of drugs for type 2 diabetes. Sivagnanam, G. // Journal of Pharmacology & Pharmacotherapeutics;Jul-Sep2013, Vol. 4 Issue 3, p224 

    The article offers information on the Sodium-glucose contransporter 2(SGLT 2) inhibitor, Invokana treatment for type 2 diabetes which have been approved by the Food and Drug Administration (FDA) in the U.S. It states that the SGLT 2 do not simulate insulin secretion and are expected to be...

  • New Way to Fight Diabetes. Freed, Steve // Chain Drug Review;8/5/2013, Vol. 35 Issue 12, p60 

    The article focuses on the introduction of Canagliflozin, a sodium glucose cotransporter 2 inhibitor, used in the treatment of diabetes. It informs that Canagliflozin was approved by the U.S. Food and Drug Administration on March 2013 to improve glycemic control in type 2 diabetes patients....

  • FDA approves lixisenatide for type 2 diabetes. Do, Vincent; Holle, Lisa M. // Drug Topics;Dec2016, Vol. 160 Issue 12, p30 

    The article offers information on the approval of drug lixisenatide by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes type II. Topics discussed include drug not be used for people who have problems with stomach emptying, postprandial glucose decreased by lixisenatide...

  • Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Häring, Hans-Ulrich; Merker, Ludwig; Seewaldt-Becker, Elke; Weimer, Marc; Meinicke, Thomas; Broedl, Uli C.; Woerle, Hans J. // Diabetes Care;Jun2014, Vol. 37 Issue 6, p1650 

    OBJECTIVE To investigate the efficacy and tolerability of empagliflozin as an add-on to metformin therapy in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Patients with HbA1c levels of ≥7% to ≤ 10% (≥53 to ≤86 mmol/mol) while receiving metformin (≥1,500...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics